EVI5 is a risk gene for multiple sclerosis

被引:0
|
作者
I A Hoppenbrouwers
Y S Aulchenko
G C Ebers
S V Ramagopalan
B A Oostra
C M van Duijn
R Q Hintzen
机构
[1] MS Centre ErasMS,Department of Neurology
[2] Genetic Epidemiology Unit,Departments of Epidemiology & Biostatistics
[3] University of Oxford,Wellcome Trust Centre for Human Genetics and Department of Clinical Neurology
[4] Clinical Genetics,undefined
来源
Genes & Immunity | 2008年 / 9卷
关键词
multiple sclerosis; genetic risk variants; EVI5;
D O I
暂无
中图分类号
学科分类号
摘要
HLA-DRB1 is the major locus associated with risk for multiple sclerosis (MS). A recent genome-wide study showed three additional single-nucleotide polymorphisms (SNPs), within the IL2RA and IL7RA genes respectively, also to be associated with MS. Consistent association but lower significance was found for 13 other SNPs. In this study, we aimed to verify association of these SNPs with MS in 46 MS patients and 194 controls from a Dutch genetically isolated population. Apart from the human leukocyte antigen locus, the EVI5 gene on chromosome 1 was confirmed as a novel risk gene, with odds ratios (ORs) even higher than those from the MS Consortium (ORs 2.01 and 1.9; P=0.01). The risk effect of EVI5 was further validated for the general MS population in an independent set of 1318 MS patients from the Canadian Collaborative Project on the Genetic Susceptibility to MS. On the basis of the transmission disequilibrium testing, a weak but significant risk effect was observed (OR 1.15; P=0.03 and OR 1.15; P=0.04). This study confirms EVI5 as another risk locus for MS; however, much of the genetic basis of MS remains unidentified.
引用
收藏
页码:334 / 337
页数:3
相关论文
共 50 条
  • [1] EVI5 is a risk gene for multiple sclerosis
    Hoppenbrouwers, I. A.
    Aulchenko, Y. S.
    Ebers, G. C.
    Ramagopalan, S. V.
    Oostra, B. A.
    van Duijn, C. M.
    Hintzen, R. Q.
    GENES AND IMMUNITY, 2008, 9 (04) : 334 - 337
  • [2] A Multiple Sclerosis Disease-Risk Variant in EVI5 Links Susceptibility to the S1P Pathway
    Didonna, Alessandro
    Isobe, Noriko
    Caillier, Stacy J.
    Li, Kathy H.
    Burlingame, Alma L.
    Hauser, Stephen L.
    Baranzini, Sergio E.
    Patsopoulos, Nikolaos A.
    Oksenberg, Jorge R.
    ANNALS OF NEUROLOGY, 2015, 78 : S62 - S63
  • [3] A non-synonymous single-nucleotide polymorphism associated with multiple sclerosis risk affects the EVI5 interactome
    Didonna, Alessandro
    Isobe, Noriko
    Caillier, Stacy J.
    Li, Kathy H.
    Burlingame, Alma L.
    Hauser, Stephen L.
    Baranzini, Sergio E.
    Patsopoulos, Nikolaos A.
    Oksenberg, Jorge R.
    HUMAN MOLECULAR GENETICS, 2015, 24 (24) : 7151 - 7158
  • [4] Ecotropic Viral Integration Site 5 (EVI5) variants are associated with multiple sclerosis in Iranian population
    Mazdeh, Mehrdokht
    Ghafouri-Fard, Soudeh
    Noroozi, Rezvan
    Sayad, Arezou
    Khani, Maryam
    Taheri, Mohammad
    Omrani, Mir Davood
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 15 - 19
  • [5] The Evi5 family in cellular physiology and pathology
    Lim, Yi Shan
    Tang, Bor Luen
    FEBS LETTERS, 2013, 587 (12) : 1703 - 1710
  • [6] Role of Evi5 in Drosophila iron metabolism
    Le Bras, Alexandra
    LAB ANIMAL, 2024, 53 (06) : 127 - 127
  • [7] The homology of EVI5 and ABK sequences among animals
    Swihart, Corrie J.
    DEVELOPMENTAL BIOLOGY, 2011, 356 (01) : 217 - 217
  • [8] Evi5 is required for Xenopus limb and tail regeneration
    Yang, Li
    Chen, Youwei
    Liu, Huahua
    Liu, Yu
    Yuan, Feng
    Li, Qianyan
    Lin, Gufa
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [9] EVI5 is a novel centrosomal protein that binds to α- and γ-tubulin
    Faitar, SL
    Dabbeekeh, JTS
    Ranalli, TA
    Cowell, JK
    GENOMICS, 2005, 86 (05) : 594 - 605
  • [10] EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells
    Tingting Cai
    Jieqi Zhou
    Yuanyuan Zeng
    Wenwen Du
    Yang Zhang
    Ting Liu
    Yulong Fu
    Jian-an Huang
    Qian Qian
    Jianjie Zhu
    Chunhua Ling
    Zeyi Liu
    Journal of Experimental & Clinical Cancer Research, 39